dupilumab
regeneron,sanofi
['dupixent', 'dupilumab', '$sny', '$regn']
dupixent (dupilumab) late-breaking phase 3 data at eadv 2022 showed significant improvements in signs and symptoms of prurigo nodularis $san $sny $regn 
Biotellytics / https://t.co/37itIfRolp = business intel service on listed European Bios / Views=mine only, RT-like=/=endorse, no advice. 16y in Tech (chip design)